Chair, The University of Texas MD Anderson Cancer Center Department of Immunology
James Allison is a co-founder of Jounce Therapeutics and currently serves as chair of The University of Texas MD Anderson Cancer Center Department of Immunology and director of the Immunotherapy Platform. A leading tumor immunologist, Dr. Allison has a longstanding interest in mechanisms of T-cell development and activation, the development of novel strategies for tumor immunotherapy and is recognized as the first person to isolate the T-cell antigen receptor protein. His research led to the clinical development of ipilimumab (Yervoy™), which was approved in 2011 by the FDA for the treatment of metastatic melanoma. Previously, he was director of the Ludwig Center for Cancer Immunotherapy and the chair of the immunology program at the Memorial Sloan-Kettering Cancer Center, as well as the David H. Koch Chair in Immunologic Studies and attending immunologist at Memorial Sloan-Kettering Cancer Center. Dr. Allison is a member of the National Academy of Sciences and the Institute of Medicine, and is a fellow of the American Academy of Microbiology and the American Association for the Advancement of Science. Previously, he served as president of the American Association of Immunologists. He has received numerous awards, including the Centeon Award for Innovative Breakthroughs in Immunology, the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology, the AAI-Dana Award in Human Immunology Research and the C. Chester Stock Award for Distinguished Achievement in Biomedical Research. Dr. Allison recently received an AACR/SU2C/CRI cancer immunotherapy dream team grant, for which he will serve as the Dream Team leader.
Dr. Allison received his B.S. in microbiology and his Ph.D. in biological sciences from the University of Texas.
Professor, Departments of Pathology and Medicine, University of Chicago
Tom Gajewski is a scientific co-founder of Jounce Therapeutics and currently serves as professor, departments of pathology and medicine, section of hematology/oncology at the University of Chicago. There, he is leader of the immunology and cancer program of the Cancer Center, and also directs the Melanoma Oncology clinic. Dr. Gajewski is the immediate past president of the Society for Immunotherapy of Cancer and serves as an editor of Cancer Research. His laboratory studies the molecular and cellular regulation of T lymphocyte activation and differentiation, and in turn applies this information to preclinical and clinical efforts to promote anti-tumor immunity in vivo. Dr. Gajewski is committed to investigating and developing new treatments for patients with melanoma, with a special interest in the development of immunotherapies against the disease. Dr. Gajewski also leads development of immune-based therapies for other cancers, using new laboratory data on how the immune system is regulated to develop novel clinical trials. He has served on the program committees for the American Society for Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR).
Dr. Gajewski received his Ph.D. and B.A. from the University of Chicago and his M.D. from the University of Chicago Pritzker School of Medicine.
Abeloff Professor of Oncology, Director, Cancer Immunology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine
Drew Pardoll is a scientific co-founder of Jounce Therapeutics and an Abeloff Professor of oncology, medicine, pathology and molecular biology and genetics at the Johns Hopkins University School of Medicine. He is also director of cancer immunology in the Sidney Kimmel Comprehensive Cancer Center. Dr. Pardoll has published more than 250 papers and more than 20 book chapters on the subject of T cell immunology and cancer vaccines. He has served on the editorial board of the Journal of the National Cancer Institute and Cancer Cell, and has served as a member of scientific advisory boards for the Cancer Research Institute, the University of Pennsylvania Human Gene Therapy Gene Institute, Biologic Resources Branch of the National Cancer Institute, Harvard-Dana Farber Cancer Center, Cerus Corporation, Global Medical Products Corporation, Genencor Corporation, CellGenesys Corporation, Mojave Therapeutics, the American Association of Clinical Oncology and the American Association of Cancer Research. Dr. Pardoll has made a number of basic advances in cellular immunology, including the discovery of gamma - delta T cells, NKT cells and interferon-producing killer dendritic cells. Over the past two decades, Dr. Pardoll has studied molecular aspects of dendritic cell biology and immune regulation, particularly related to mechanisms by which cancer cells evade elimination by the immune system. He is an inventor of a number of immunotherapies, including GVAX cancer vaccines and Listeria monocytogenes based cancer vaccines. Dr. Pardoll's basic immunology discoveries include the identification of γδ-T cells, NKT cells and IKDC. He elucidated the role of Stat3 signaling in tumor immune evasion and in Th17 development, leading to the discovery that Stat3-driven Th17 responses promote carcinogenesis. Dr. Pardoll discovered one of the two ligands for the PD-1 inhibitory receptor and leads the Hopkins cancer immunology program that developed PD-1 pathway-targeted antibodies, demonstrating their clinical activity in multiple cancer types. His more than 250 articles cover cancer vaccines, gene therapies, cancer prevention technologies, recombinant immune modulatory agents for specific pathways that regulate immunity to cancer and infectious diseases.
Dr. Pardoll completed his M.D., Ph.D., medical residency and oncology fellowship at Johns Hopkins University.
Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Leading cancer immunotherapy translational scientist Pam Sharma is a co-founder of Jounce Therapeutics and currently serves as an associate professor in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center and is the director of the Flow Cytometry Facility in the Koch Center. Additionally, she serves as an associate professor in the Department of Immunology, Division of Cancer Medicine at the MD Anderson Cancer Center, is a faculty member of The University of Texas Graduate School of Biomedical Sciences, and co-director of the Immunotherapy Platform. Previously, she served as associate clinical director at the Ludwig Center for Cancer Immunotherapy at Memorial Sloan-Kettering Cancer Center. Dr. Sharma is a medical oncologist and immunologist, and is currently the principal investigator of several immunotherapy clinical trials, which allow her to further investigate immune responses and pathways that are critical for eliciting anti-tumor responses and clinical benefit in cancer patients. Dr. Sharma has received numerous awards in her field including the MD Anderson Cancer Center 2012 Faculty Scholar Award. Dr. Sharma is also an investigator on the recently awarded AACR/SU2C/CRI cancer immunotherapy dream team grant.
Dr. Sharma holds a Ph.D. in immunology and an M.D. from Pennsylvania State University. She also holds a B.A. in biology and an M.A. in biotechnology from Boston University.
Director, Georgetown Lombardi Comprehensive Cancer Center, Professor and Chair, Department of Oncology, Georgetown University Medical Center
Internationally recognized medical oncologist Louis Weiner is a scientific co-founder of Jounce Therapeutics and an accomplished researcher developing novel immunotherapy treatments in his laboratory. As director of the Lombardi Comprehensive Cancer Center, professor and chair of the department of oncology, Francis L. and Charlotte G. Gragnani Chair and associate vice president of Georgetown University Medical Center, Dr. Weiner is responsible for the operation and development of the cancer center, including its educational, research and clinical missions. Dr. Weiner is recognized for his laboratory and clinical research focusing on new therapeutic approaches that mobilize the patient's immune system to fight cancer using monoclonal antibodies, and the use of functional genomics tools to improve the anti-tumor consequences of antibody-targeted therapy. Prior to Lombardi, Dr. Weiner served as chairman of the medical oncology department and vice president for Translational Research at Fox Chase Cancer Center in Philadelphia, where he held an endowed chair in medical science and was the driving force behind developing an immunotherapy laboratory and clinical program, as well as establishing the Center's medical oncology fellowship program. Dr. Weiner has published more than 150 scientific papers and lectures extensively on targeted therapies for cancer. He served as Fox Chase Cancer Center's principal investigator for the Eastern Cooperative Oncology Group (ECOG) from 1994 until 2002, a major national study group working to improve cancer treatment through clinical trials. Dr. Weiner is the founding and past chair of the Cancer Immunology Working Group of the American Association of Cancer Research, as well as past course co-director for the annual AACR/ASCO Clinical Methods Workshop. He serves on the NCI Board of Scientific Counselors, and on the NExT Oversight Committee. Dr. Weiner is also serves on several journal editorial boards, including Cancer Research and Clinical Cancer Research.
Dr. Weiner received his M.D. from Mount Sinai School of Medicine at New York University and his B.A. in biology from the University of Pennsylvania.
Alumni Endowed Professor of Pathology and Immunology and Professor of Molecular Microbiology, Washington University School of Medicine
A leader in the study of tumor immunology, Bob Schreiber is a scientific adviser to Jounce Therapeutics and currently serves as the alumni endowed professor of pathology and immunology, professor of molecular microbiology and the tumor immunology program co-leader for the Siteman Comprehensive Cancer Center at Washington University School of Medicine. He is an affiliate of the Ludwig Institute for Cancer Research, an associate director of the Cancer Research Institute, a member of the American Academy of Arts and Sciences, a fellow of the American Association of Science, a past member of the board of scientific advisers for the National Cancer Institute and a past president of the Society for Leukocyte Biology. Dr. Schreiber has led a major revision in our understanding of how the immune system interacts with cancer. His work on the cancer immunoediting hypothesis has helped reveal that the immune system is not only capable of destroying cancers, but can also drive them into a dormant state and, in some cases, can sculpt the immunogenicity of tumors so as to enhance results in an enhancement of their malignancy. His lab is highly regarded for its research on the molecular cell biology and immunology of interferon-gamma and its receptor, as well as its strong expertise in mAb discovery. Dr. Schreiber's group unequivocally demonstrated that the immune system provides an extrinsic tumor suppressor function (cancer immunosurveillance) capable of eliminating spontaneous- and carcinogen-induced primary tumors. He has authored more than 200 peer reviewed and invited publications and has received several honors, including the Milstein Award for Outstanding Achievements in Research on Interferon and Cytokines from the International Society of Interferon and Cytokine Research, the Bonazinga Award for Excellence in Leukocyte Biology Research from the Society for Leukocyte Biology, the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology from the Cancer Research Institute and the Charles Rodolphe Brupbacher Award for Cancer Research from the Brupbacher Cancer Foundation in Switzerland.
Dr. Schreiber holds a B.A. in chemistry and Ph.D. in biochemistry from the State University of New York at Buffalo.